Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab immunotherapy.

R Schilder

    Cancer Biotherapy & Radiopharmaceuticals
    |June 13, 2000
    PubMed
    Summary
    This summary is machine-generated.

    New treatments like rituximab offer a favorable toxicity profile for lymphoma patients, improving quality of life. Further research into targeted therapies like vaccines promises enhanced efficacy with reduced side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    NCCN Practice Guidelines for Chronic Myelogenous Leukemia.

    Oncology (Williston Park, N.Y.)·2001
    Same author

    Gynecological cancers.

    Cancer chemotherapy and biological response modifiers·2000
    Same author

    Anaphylaxis during autologous peripheral blood progenitor cell infusion.

    Bone marrow transplantation·1997
    Same author

    Gynecologic cancers.

    Cancer chemotherapy and biological response modifiers·1997
    Same author

    Improved method for infusing cells.

    Bone marrow transplantation·1995
    Same author

    Phase I trial of ilmofosine as a 24 hour infusion weekly.

    Investigational new drugs·1995
    Same journal

    Review of Glypican-3-Targeted Imaging Agents for Hepatocellular Carcinoma.

    Cancer biotherapy & radiopharmaceuticals·2026
    Same journal

    Clinical Laboratory Evaluation of the Biodistribution of a Radiolabeled Antimicrobial Peptide for Precision Radiopharmaceutical-Guided Radionuclide Therapy in Severe Pneumonia Among Immunocompromised Patients with Cancer.

    Cancer biotherapy & radiopharmaceuticals·2026
    Same journal

    Single-Cell Transcriptomics in Triple-Negative Breast Cancer: Implications for Radionuclide Therapy in Precision Oncology.

    Cancer biotherapy & radiopharmaceuticals·2026
    Same journal

    Curved Vertebroplasty System Combined with Targeted Radionuclide Therapy for Tumor-Related Pathological Vertebral Fractures.

    Cancer biotherapy & radiopharmaceuticals·2026
    Same journal

    Development of a Freeze-Dried Bevacizumab Kit for <sup>99m</sup>Tc Radiolabeling and Preclinical Evaluation <i>In Vitro</i> and in Normal Mice.

    Cancer biotherapy & radiopharmaceuticals·2026
    Same journal

    Radionuclide-Based Theranostic Mapping for Spatially Optimized Treatment Planning in Cervical Carcinoma.

    Cancer biotherapy & radiopharmaceuticals·2026
    See all related articles

    Area of Science:

    • Oncology
    • Immunology

    Background:

    • Low-grade lymphoma remains largely incurable for most patients, necessitating treatment strategies that balance efficacy and toxicity.
    • Established treatments like allogeneic bone marrow transplantation and nonablative donor lymphocyte infusions offer curative potential but are suitable for a limited patient subset.

    Discussion:

    • Rituximab presents a novel therapeutic option for lymphoma, characterized by a favorable toxicity profile and outpatient administration, positively impacting patient quality of life.
    • Radioimmunotherapy strategies involving rituximab are emerging as promising new directions in non-Hodgkin's lymphoma treatment.
    • The development of targeted therapies, including vaccines and cell activity modulators, aims to increase treatment specificity and minimize toxicity.

    Key Insights:

    • Rituximab demonstrates a favorable toxicity profile and improves quality of life in lymphoma management.

    Related Experiment Videos

  • Emerging strategies like radioimmunotherapy and targeted vaccines hold promise for more specific and less toxic lymphoma treatments.
  • Rituximab may also provide insights into the cellular regulation of normal and malignant B cells.

    • Outlook:

    • Future lymphoma therapies are expected to achieve a superior therapeutic index through increased treatment specificity and reduced toxicity.
    • Continued research into novel agents and therapeutic modalities will further refine lymphoma management.
    • Understanding B-cell regulation and dysregulation is crucial for developing next-generation lymphoma treatments.